Tumor Immunology and Immunotherapy - Integrated Methods Part A

Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College, Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine, Honorary Associate Professor with the Faculty of Medicine of the University of Paris, and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara, the Graduate School of Pharmacological Sciences of the University of Padova, and the Graduate School of Network Oncology and Precision Medicine of the University of Rome “La Sapienza”. Moreover, he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology.Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals:OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience. Nils-Petter Rudqvist received his M.Sc. (Physics, 2009) and Ph.D. (Medical Science, 2015) from the University of Gothenburg, Sweden. He decided to pursue an academic career and continue with his postdoctoral training in US. He first joined the Center for Radiological Research at Columbia University in New York where he studied gene signatures of radiation exposure. He then moved to Weill Cornell Medicine to join the program in radiation and immunity under the mentorship of Dr. Demaria. His current research is focused on investigating which neoantigens are key targets of the radiation-induced anti-tumor T cell response in mice and in patients treated with radiotherapy and immune checkpoint blockade. He recently demonstrated in a mouse model that radiation therapy diversifies the TCR repertoire of tumor infiltrating lymphocytes, an effect crucial for its synergy with immune checkpoint blockade treatment. Nils-Petter has also defined unique patters of expansion of TCR clonotypes in patients who respond or not to treatment with radiotherapy and ipilimumab. He has published 20 articles in peer-reviewed scientific journals and 60+ scientific conference abstracts.

• 1. High-dimensional multiplexed immunohistochemical characterization of immune contexture in human cancersGrace Banik, Courtney B. Betts, Shannon M. Liudahl, Shamilene Sivagnanam, Rie Kawashima, Tiziana Cotechini, William Larson, Jeremy Goecks, Sara I. Pai, Daniel R. Clayburgh, Takahiro Tsujikawa and Lisa M. Coussens2. Multiplex immunohistochemistry assay to evaluate the melanoma tumor microenvironmentGiosuè Scognamiglio, Mariaelena Capone, Domenico Mallardo, Gerardo Botti, Paolo A. Ascierto and Gabriele Madonna3. Characterization of the immune microenvironment of NSCLC by multispectral analysis of multiplex immunofluorescence imagesMichael Surace, Lorenz Rognoni, Jaime Rodriguez-Canales and Keith E. Steele4. Multiplexed immunohistochemistry for immune cell phenotyping, quantification and spatial distribution in situAngela Vasaturo and Jérôme Galon5. Multiplex immunohistochemistry as a novel tool for the topographic assessment of the bone marrow stem cell nicheMarcus Bauer, Christoforos Vaxevanis, Daniel Bethmann, Chiara Massa, Nikolaos Pazaitis, Claudia Wickenhauser and Barbara Seliger6. Deconvolution of the immunological contexture of mouse tumors with multiplexed immunohistochemistryIleana S. Mauldin, Natasha D. Sheybani, Samuel J. Young, Richard J. Price and Craig L. Slingluff7. Tracing bone marrow-derived microglia in brain metastatic tumorsWei Du and Paula D. Bos8. Monitoring abscopal responses to radiation in miceMaria Esperanza Rodriguez-Ruiz, Takahiro Yamazaki, Aitziber Buqué, Norma Bloy, Viviane A. O. Silva, Lena Stafford, Ai Sato and Lorenzo Galluzzi9. Methods to assess anticancer immune responses in orthotopic bladder carcinomasRandy F. Sweis10. Characterization of conventional dendritic cell populations in preclinical tumor models using flow cytometryErik Wennerberg, Nils Rudqvist and Sheila Spada11. Quantitative evaluation of tumor-specific T cells in tumors and lymphoid tissuesKathleen M. Kokolus, Nataša Obermajer and Pawel Kalinski12. Generation and validation of recombinant herpes simplex type 1 viruses (HSV-1) using CRISPR/Cas9 genetic disruptionPraveen K. Bommareddy, Cole Peters and Howard L. Kaufman13. Production and use of adeno-associated virus vectors as tools for cancer immunotherapyMyriam Fernandez-Sendin, Shirley Tenesaca, Marcos Vasquez, Fernando Aranda and Pedro Berraondo14. Modulation of the tumor microenvironment with an oncolytic adenovirus for effective T-cell therapy and checkpoint inhibitionJoão Manuel Santos, Riikka Havunen and Akseli Hemminki15. Genetic modification of oncolytic viruses to enhance antitumor immunityMaria Eugenia Davola, Alyssa Vito, Jiarun Wei, Nader El-Sayes, Samuel Workenhe and Karen Louise Mossman16. CRISPR technology for immuno-oncology applicationsJianbin Wang, Vitaly Balan and Francesco Marincola17. Neoantigen prediction from genomic and transcriptomic dataSebastiano Battaglia18. Monitoring antigen cross-presentation with human dendritic cells purified from the bloodStephane Isnard, Etienne Hatton, Jean-Baptiste Guillerme and Anne Hosmalin